Drug Trial Radar · NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,580
Planned (sponsor's estimate)
Start
Jan 7, 2025
Primary completion
Jan 2029
Study completion Dec 2031
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Conditions
- Non-small Cell Lung Cancer
Interventions
PumitamigDrug
Intravenous infusion
PembrolizumabDrug
Intravenous infusion
CarboplatinDrug
Intravenous infusion
PemetrexedDrug
Intravenous infusion
PaclitaxelDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEsTime frame: From the first dose of the investigational medicinal product (IMP) to the 90-day Follow-Up Visit
- Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)Time frame: From the first dose of IMP to the 90-day Follow-Up Visit
- Phase 2 - Objective response rate (ORR)Time frame: Up to approximately 2 years
- Phase 2 - Best percentage change from baseline in tumor sizeTime frame: Up to approximately 2 years
- Phase 3 - Progression free survival (PFS) assessed by BICRTime frame: Up to approximately 5 years
Locations
366 sites in 22 countries. Site status is shown where the registry gives one.
Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology
Birmingham, Alabama · Recruiting
Alaska Oncology and Hematology, LLC
Anchorage, Alaska · Recruiting
John Muir Clinical Research Center
Concord, California · Recruiting
University Of California - San Diego Moores Cancer Center
La Jolla, California · Recruiting
Vail Health
Vail, Colorado · Recruiting
MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)
Washington D.C., District of Columbia · Recruiting
MEDSTAR Washington Hospital Center (MedStar Health Research Institute)
Washington D.C., District of Columbia · Recruiting
Clermont Oncology Center
Clermont, Florida · Recruiting
SSAK Partners, LLC.
Coral Springs, Florida · Recruiting
Baptist Medical Center Jacksonville
Jacksonville, Florida · Recruiting
Mid Florida Cancer Centers
Orange City, Florida · Recruiting
Cleveland Clinic Florida - Martin North Hospital
Stuart, Florida · Recruiting
H. Lee Moffit Cancer center and research institute
Tampa, Florida · Recruiting
Cleveland Clinic Weston Hospital
Weston, Florida · Recruiting
Northwest Georgia Oncology Centers, P.C.
Marietta, Georgia · Recruiting
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana · Recruiting
Indiana University Health University Hospital
Indianapolis, Indiana · Recruiting
Physicians Clinic of Iowa
Cedar Rapids, Iowa · Recruiting
Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Baptist Health Hardin
Elizabethtown, Kentucky · Recruiting
Baptist Health Lexington
Lexington, Kentucky · Recruiting
University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center)
Lexington, Kentucky · Recruiting
Frederick Health Hospital- James M Stockman Cancer Institute
Frederick, Maryland · Recruiting
Missouri Cancer Associates
Columbia, Missouri · Recruiting
SSM Health Cancer Care - St. Clare
Fenton, Missouri · Withdrawn
Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC)
Hastings, Nebraska · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Summit Medical Group PA
Florham Park, New Jersey · Recruiting
The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion
Paramus, New Jersey · Recruiting
Nuvance Health
Poughkeepsie, New York · Recruiting
Suny-Stony Brook University Cancer Center
Stony Brook, New York · Recruiting
White Plains Hospital
White Plains, New York · Recruiting
Fletcher Hospital, Inc. dba AdventHealth Hendersonville
Hendersonville, North Carolina · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
The Christ Hospital Cancer Center
Cincinnati, Ohio · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Dayton Physicians Network
Dayton, Ohio · Recruiting
Kettering Medical Center
Kettering, Ohio · Recruiting
Showing 40 of 366 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.